동맥류 코일링 및 색전 기기 시장 - 세계 예측(2026-2032년)

The Aneurysm Coiling & Embolization Devices Market is projected to grow by USD 3.18 billion at a CAGR of 8.78% by 2032.

Executive Introduction to Aneurysm Coiling & Embolization Devices

Aneurysm coiling and embolization devices are central to minimally invasive neurovascular care, enabling endovascular treatment of intracranial aneurysms and selected vascular malformations through detachable coils, liquid embolic agents, stent-assisted systems, balloon remodeling techniques, and flow-diversion adjuncts. Demand is being shaped by the clinical priority to prevent aneurysmal subarachnoid hemorrhage, reduce procedural morbidity compared with open surgery in eligible patients, and improve long-term occlusion durability for complex, wide-neck, bifurcation, and ruptured aneurysms. Peer-reviewed evidence and professional society guidance continue to support endovascular therapy as a core treatment pathway, while device innovation is increasingly focused on deliverability, thrombogenic control, coil softness, radiopacity, aneurysm neck coverage, and compatibility with advanced imaging and microcatheter platforms. The executive outlook for aneurysm coiling and embolization devices is defined by rising neurointerventional capability, earlier aneurysm detection through high-resolution CT angiography and MR angiography, expansion of comprehensive stroke centers, and stronger emphasis on outcomes measurement, operator training, and post-procedure surveillance.

Transformative Shifts in the Aneurysm Treatment Landscape

The aneurysm coiling and embolization device landscape is undergoing a structural shift from standalone coil packing toward integrated aneurysm management strategies that combine coils with neck-bridging devices, adjunctive stents, balloons, and flow-modifying technologies. Clinical decision-making is becoming more anatomy-specific, with treatment selection influenced by rupture status, dome-to-neck ratio, aneurysm location, parent vessel morphology, thromboembolic risk, and need for antiplatelet therapy. At the same time, hospitals are strengthening biplane angiography capacity, adopting 3D rotational angiography and cone-beam CT, and standardizing peri-procedural anticoagulation and antiplatelet protocols to reduce complications. Regulatory scrutiny is also intensifying around real-world safety evidence, device traceability, material performance, and post-market clinical follow-up. Procurement teams are prioritizing product reliability, training support, procedural efficiency, and inventory breadth across coil sizes, softness grades, detachable systems, and embolic formulations. These shifts are pushing manufacturers and care providers toward evidence-led innovation, multidisciplinary aneurysm boards, and treatment pathways that balance durable occlusion with preservation of branch vessels and perforators.

Cumulative Impact of Artificial Intelligence on Aneurysm Embolization

Artificial intelligence is beginning to influence the aneurysm coiling and embolization ecosystem across detection, planning, workflow optimization, and outcomes assessment. In imaging, AI-supported algorithms are being evaluated to assist radiologists and neurointerventional teams in identifying intracranial aneurysms on CTA, MRA, and digital subtraction angiography, particularly where small aneurysms or complex vascular anatomy create interpretation challenges. In procedural planning, computational modeling and AI-assisted segmentation can support measurement of aneurysm neck, dome, vessel diameter, inflow zone, and device sizing considerations, although clinical oversight remains essential. AI is also strengthening quality management by enabling structured case review, complication tracking, recurrence assessment, and longitudinal surveillance after coil embolization. The cumulative impact is not a replacement of physician judgment but an augmentation of neurovascular decision-making through faster image triage, more consistent anatomical characterization, improved documentation, and potentially more personalized follow-up schedules. Adoption remains dependent on validation, interoperability with angiography and radiology systems, explainability, cybersecurity, and regulatory clearance for specific clinical use cases.

Key Regional Insights Across Global Neurovascular Device Adoption

In Asia-Pacific, growth in aneurysm coiling and embolization procedures is supported by expanding tertiary hospitals, increased stroke and neurovascular service development, and rapid uptake of advanced imaging in countries such as China, India, Japan, South Korea, and Australia, although access remains uneven between metropolitan and rural settings. North America is characterized by mature neurointerventional infrastructure, comprehensive stroke center networks, high utilization of endovascular aneurysm repair techniques, and strong emphasis on post-market evidence, physician credentialing, and reimbursement-linked documentation. Latin America is advancing through improved access to interventional neuroradiology in major urban centers, with Mexico and Brazil serving as important hubs for complex neurovascular care, while budget constraints and specialist availability continue to influence device adoption. Europe benefits from established clinical guidelines, cross-border research collaboration, and widespread availability of endovascular aneurysm treatment in leading health systems, with adoption shaped by national procurement policies and health technology assessment expectations. The Middle East is building capacity through investments in specialized hospitals, stroke programs, and medical education, particularly in Gulf countries, while Africa faces the greatest access disparities, with aneurysm embolization concentrated in select referral centers and constrained by angiography infrastructure, device affordability, and workforce limitations.

Key Economic and Strategic Group Insights for Neurovascular Markets

ASEAN countries are expanding aneurysm coiling and embolization access through modernization of tertiary hospitals and regional neurovascular training, though device availability and reimbursement maturity differ significantly across member states. The GCC is strengthening demand through investment in advanced hospital infrastructure, specialist recruitment, and national strategies to reduce the burden of stroke and complex neurological disease, creating favorable conditions for endovascular aneurysm services. The European Union is shaped by harmonized medical device regulatory requirements, strong clinical governance, and structured post-market surveillance, placing high importance on safety, performance, and real-world evidence for coils, embolic systems, and adjunctive devices. BRICS countries represent a diverse opportunity landscape, combining large patient populations and expanding imaging access with varied reimbursement systems, domestic manufacturing priorities, and disparities in specialist distribution. G7 markets remain highly influential in clinical protocol development, regulatory expectations, device innovation, and physician training, reflecting mature healthcare systems and substantial neurointerventional expertise. NATO member countries, while not a healthcare market bloc, include many advanced health systems where defense-linked trauma, emergency preparedness, and high-acuity hospital networks can indirectly support sophisticated endovascular capability and resilient medical technology supply chains.

Key Country Insights Shaping Aneurysm Coiling & Embolization Demand

The United States maintains one of the most developed environments for aneurysm coiling and embolization devices, supported by comprehensive stroke centers, advanced angiography suites, robust clinical research activity, and structured reimbursement pathways for endovascular procedures. Canada shows strong adoption in major academic and provincial referral centers, with access influenced by regional health system planning and specialist availability. Mexico is expanding capabilities in urban private and public hospitals, while Brazil anchors much of Latin America's advanced neurointerventional activity through major tertiary care networks. In Europe, the United Kingdom emphasizes guideline-driven care and centralized specialist services; Germany combines strong hospital infrastructure with high procedural sophistication; France supports structured neurovascular care pathways; Russia has advanced centers in major cities but uneven regional access; Italy and Spain maintain established interventional neuroradiology communities within national healthcare systems. In Asia-Pacific, China is rapidly expanding neurovascular infrastructure and physician training, India is increasing access through large metropolitan hospital networks while facing affordability and geographic access challenges, Japan demonstrates mature endovascular expertise and high technology adoption, Australia offers advanced care through specialized public and private centers, and South Korea is recognized for sophisticated hospital systems, imaging adoption, and strong neurointerventional practice. Across all countries, device uptake is closely linked to aneurysm detection rates, emergency stroke pathways, operator experience, angiography availability, procurement systems, and long-term follow-up capacity.

Actionable Recommendations for Aneurysm Device Industry Leaders

Industry leaders should prioritize clinically differentiated innovation that addresses complex aneurysm anatomy, recurrence reduction, procedural safety, and compatibility with evolving microcatheter and imaging workflows. Product strategies should be supported by rigorous clinical evidence, real-world registries, post-market surveillance, and transparent reporting of occlusion durability, retreatment rates, thromboembolic events, hemorrhagic complications, and device-related adverse outcomes. Commercial teams should strengthen education programs for neurointerventionalists, nurses, and technologists, focusing on device selection, sizing, deployment technique, antiplatelet management, and complication response. Regional strategies should reflect differences in reimbursement, tendering, angiography infrastructure, and workforce maturity rather than applying uniform launch models. Leaders should also invest in AI-ready data integration, simulation-based training, supply chain resilience, and portfolio breadth across coils, embolic agents, adjunctive stents, balloons, and flow-modifying tools. Partnerships with hospitals and academic centers should focus on standardized protocols, measurable outcomes, and equitable access to advanced aneurysm treatment.

Research Methodology for Evidence-Based Neurovascular Market Insights

This executive summary is developed through a structured secondary research approach grounded in verified clinical, regulatory, and healthcare infrastructure sources. The analysis draws on peer-reviewed medical literature, neurointerventional guidelines, public regulatory documents, health authority publications, hospital care pathway information, clinical trial registries, and recognized epidemiological and stroke-care resources. Insights are synthesized to identify qualitative trends in technology adoption, regional access, procedural practice, AI integration, and care delivery without presenting market estimation, market sizing, market share, or forecasting. The methodology emphasizes triangulation of evidence across clinical outcomes, device use cases, imaging advances, regulatory expectations, and regional healthcare capacity. Particular attention is given to intracranial aneurysm treatment pathways, endovascular embolization techniques, post-procedure surveillance, and documented variations in access to neurovascular services across regions and countries.

Conclusion: The Future of Aneurysm Coiling & Embolization Devices

Aneurysm coiling and embolization devices remain essential to modern neurovascular intervention, with innovation increasingly centered on precision, safety, durability, and anatomy-specific treatment. The field is progressing from device-centric procedures toward integrated care models that combine advanced imaging, multidisciplinary decision-making, operator expertise, real-world evidence, and selective use of AI-enabled tools. Regional and country-level adoption will continue to depend on infrastructure, reimbursement, trained specialists, regulatory pathways, and equitable access to high-acuity neurovascular care. For industry participants, the strongest opportunities lie in clinically validated technologies, education-led adoption, resilient supply chains, and partnerships that improve procedural quality and patient outcomes. Sustained success will require alignment with evidence-based medicine, regulatory rigor, and the practical needs of neurointerventional teams treating both ruptured and unruptured intracranial aneurysms.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Aneurysm Coiling & Embolization Devices Market, by Product Type

• 7.1. Introduction
• 7.2. Coils
  • 7.2.1. Bare Platinum
  • 7.2.2. Bioactive
  • 7.2.3. Hydrogel Coated
    • 7.2.3.1. Multi Layer
    • 7.2.3.2. Single Layer
• 7.3. Flow Diverters
• 7.4. Liquid Embolics
  • 7.4.1. NBCA
  • 7.4.2. Onyx

8. Aneurysm Coiling & Embolization Devices Market, by Procedure Type

• 8.1. Introduction
• 8.2. Elective
• 8.3. Emergency

9. Aneurysm Coiling & Embolization Devices Market, by Material Type

• 9.1. Introduction
• 9.2. Platinum Based Devices
• 9.3. Nickel Titanium Alloys
• 9.4. Stainless Steel Devices
• 9.5. Polymer Based Devices
• 9.6. Hydrogel Based Materials

10. Aneurysm Coiling & Embolization Devices Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Aneurysm Coiling & Embolization Devices Market, by Sales Channel

• 11.1. Introduction
• 11.2. Offline
• 11.3. Online

12. Aneurysm Coiling & Embolization Devices Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Aneurysm Coiling & Embolization Devices Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Aneurysm Coiling & Embolization Devices Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Acandis GmbH
• 16.2. Achieva Medical
• 16.3. ASAHI INTECC CO LTD
• 16.4. B. Braun SE
• 16.5. Balt Extrusion SAS
• 16.6. Boston Scientific Corporation
• 16.7. Cerus Endovascular Ltd
• 16.8. Cook Group Inc
• 16.9. Evasc Neurovascular
• 16.10. Imperative Care Inc
• 16.11. Johnson & Johnson Services Inc
• 16.12. Kaneka Corporation
• 16.13. Lepu Medical Technology Beijing Co Ltd
• 16.14. Medikit Co Ltd
• 16.15. Medtronic plc
• 16.16. Meril Life Sciences Pvt Ltd
• 16.17. Merit Medical Systems Inc
• 16.18. MicroPort Scientific Corporation
• 16.19. MicroVention Inc
• 16.20. Penumbra Inc
• 16.21. phenox GmbH
• 16.22. Rapid Medical Ltd
• 16.23. Shape Memory Medical Inc
• 16.24. Spartan Micro Inc
• 16.25. Stryker Corporation
• 16.26. Terumo Corporation
• 16.27. W. L. Gore & Associates Inc
• 16.28. Wallaby Medical
• 16.29. Zylox Tonbridge Medical Technology Co Ltd